Treating multidrug-resistant psoriasis with brodalumab, apremilast, methotrexate and prednisone combination therapy in the COVID-19 pandemic

Dermatol Ther. 2020 Nov;33(6):e14464. doi: 10.1111/dth.14464. Epub 2020 Nov 8.

Affiliations

¹ Department of Dermatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
² Department of Pathology, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
³ Department of Pharmacy, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
⁴ Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain.

PMID: 33112014
DOI: 10.1111/dth.14464

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Antibodies, Monoclonal, Humanized / administration & dosage
COVID-19 / epidemiology*
Drug Resistance, Multiple
Drug Therapy, Combination
Female
Humans
Methotrexate / administration & dosage
Prednisone / administration & dosage
Psoriasis / drug therapy*
SARS-CoV-2*
Thalidomide / administration & dosage
Thalidomide / analogs & derivatives

Substances

Antibodies, Monoclonal, Humanized
Thalidomide
brodalumab
apremilast
Prednisone
Methotrexate